FOXP3 is a unique marker for CD4 þ CD25 þ regulatory T cells (Tregs). In solid tumours, high numbers of Tregs are associated with a poor prognosis. Knowledge about the implications of Tregs for the behaviour of haematological malignancies is limited. In this study, skin biopsies from 86 patients with mycosis fungoides (MF) and cutaneous T-cell lymphoma (CTCL) unspecified were analysed for the expression of FOXP3 on tumour cells and tumour-infiltrating Tregs. Labelling of above 10% of the neoplastic cells was seen in one case classified as an aggressive epidermotropic CD8 þ cytotoxic CTCL. In the remaining 85 cases, the atypical neoplastic infiltrate was either FOXP3 negative (n ¼ 80) or contained only very occasional weakly positive cells (n ¼ 5). By contrast, all biopsies showed varying numbers of strongly FOXP3 þ tumour-infiltrating Tregs. MF with early or infiltrated plaques had significantly higher numbers of FOXP3 þ Tregs than CTCL unspecified or advanced MF with tumours or transformation to large cell lymphoma. An analysis of all patients demonstrated that increasing numbers of FOXP3 þ Tregs were associated with improved survival in both MF and CTCL unspecified. In conclusion, our data indicate that the presence of FOXP3 þ Tregs in CTCL is associated with disease stage and patient survival.
Introduction
FOXP3 of the forkhead box transcription factor family is now recognized as a unique marker for regulatory T cells (Tregs). The majority of these cells are CD4 þ CD25 þ T cells. They comprise 5-10% of the peripheral CD4 þ T cells in normal mice and humans. They respond to self-antigens, infectious agents and transplantation antigens, and are defined as a T-cell population that can influence other cell types with suppression of the immune response. 1, 2 In both humans and mice a lack of functional FOXP3 leads to fatal autoimmune, allergic and inflammatory diseases. In humans, a multi-organ autoimmune disease, known as the IPEX syndrome (an inheritable X-linked syndrome characterized by immune deregulation, polyendocrinopathy and enteropathy) has been associated with inherited defects in the FOXP3 gene. 3 Recent evidence has shown that Treg-mediated immune suppression is also an important method for immune evasions of tumours and a significant obstruction for successful immunotherapy against cancer. 4, 5 In keeping with this, there have been several studies showing that increased numbers of Tregs are associated with poor prognosis and decreased survival in several types of carcinoma. 6 More controversial results have been obtained in haematological malignancies. For example, in Hodgkin's lymphoma, it has been shown that low infiltration of FOXP3 þ Tregs together with high numbers of TIA-1 þ cells is associated with poor outcome. 7 Similarly, high numbers of infiltrating FOXP3 þ Tregs has been associated with improved survival in follicular lymphoma. 8 These studies have suggested that tumour-infiltrating Tregs in lymphoma may act to suppress not only tumour-infiltrating cytotoxic cells, but also the malignant cells, and that the implications of Tregs for the behaviour of these conditions are therefore more complex than for solid tumours.
Knowledge about FOXP3 expression in cutaneous T-cell lymphoma (CTCL) is limited. Using an in vitro approach, Berger et al. 9 showed that CD4 þ CTCL cells could be induced to adopt a Treg phenotype and function upon prolonged cocultivation with autologous immature dendritic cells loaded with apoptotic tumour cells. Subsequent reports have indicated that the neoplastic cells in biopsies from CTCL are usually FOXP3 negative. 10, 11 Interesting, however, preliminary data suggest that the proportion of tumour-infiltrating Tregs in CTCL correlates inversely with the disease stage and tumour burden, suggesting that Tregs may have implications for the course and behaviour of these diseases. 10 To address this hypothesis, we analysed skin biopsies from 86 CTCL patients by immunohistology for FOXP3 expression in tumour cells and tumour-infiltrating Tregs. The results show that high numbers of tumour-infiltrating FOXP3 þ Tregs are associated with superior survival in patients with both mycosis fungoides (MF) and CTCL unspecified. By contrast the neoplastic cells in these diseases are generally FOXP3 negative.
Materials and methods

Patients and tissue samples
Biopsies from all patients diagnosed with CTCL during the period 1979-2004 were drawn from the archives of the Departments of Pathology at Rigshospitalet and Bispebjerg Hospitals. A total of 135 cases were retrieved. Following review of the histological samples and the clinical records, 86 cases with either MF (n ¼ 69) or CTCL unspecified (n ¼ 17) were selected for further analysis. The patients were 45 males and 28 females with a median age of 66 years (range 33-88 years) at diagnosis. Survival data could be retrieved for 54 (63%) of the patients, including 9 of 10 patients with early MF plaques, 23 of 42 MF patients with infiltrated plaques, 6 of 10 cases with tumour MF, 6 of 7 patients with transformed MF and 9 of 17 cases with CTCL unspecified.
Histological review of biopsies and control tissues
From all 86 cases, formalin-fixed, paraffin-embedded tissue samples were reviewed by histology and immunohistochemistry, using as a minimum CD3, CD4, CD8, CD30, CD56, TIA-1 and granzyme B. Classification was performed by two of the authors (LMG and ER) in accordance with the World Health Organization and European Organization for Research and Treatment of Cancer (2005). A total of 69 patients had MF and 17 were primary CTCL unspecified. Early plaque lesions were found in 10 patients with MF, 42 had infiltrated plaques, 10 patients had tumours and 7 patients had MF with transformation to large T-cell lymphomas. Five of these were positive for CD30. Of the 17 cases with unspecified CTCL, 2 cases had primary cutaneous small-to medium-sized CD4 þ CTCL, 2 patients had primary cutaneous gd T-cell lymphoma and 1 case was consistent with a primary cutaneous aggressive epidermotropic CD8 þ cytotoxic T-cell lymphoma. The remaining CTCL, unspecified were a heterogeneous group of neoplasms consisting of CD30-negative, medium to large, pleomorphic cells with varying expression of CD4 and CD8. Four were CD4 þ , CD8À; three were CD4 þ , CD8 þ ; two were CD8 þ , CD4À and three cases were double negative. A multi-block, containing samples of reactive lymph nodes and tonsils was used as control.
Cell lines
Cell lines derived from patients with MF, normal peripheral T lymphocytes from an MF patient and two T cell lines from healthy donors (a CD4 þ CD25 þ Treg cell line and a CD4 þ TH1-like cell line) were as described in detail elsewhere. [12] [13] [14] [15] The Jurkat cell line was transfected with haemagglutinin (HA)-tagged FOXP3 or a vector control as described. 16 
Western blotting for FOXP3
Cells were rapidly pelleted and lysed in ice-cold lysis buffer (1% NP-40, 20 mM TRIS-HCl (pH 8.0), 140 mM NaCl, 10% glycerol, including the following inhibitors: 1 mM phenylmethylsulfonyl fluoride, 1 mM Na 3 VO 4 , 10mM NaF, 1 mM iodioacetamide, 5 mM EDTA, and 7.5 mg ml À1 aprotinin). To ensure equal loading, the total protein concentration of each sample was determined by Bio-Rad Protein Assay (#500-0001). Sodium dodecyl sulphate (SDS) sample buffer was added to the lysates, which were subsequently subjected to 10% SDS-polyacrylamide gel electrophoresis (PAGE) and transferred onto nitrocellulose membranes as previously described. 16 Blots were evaluated by using enhanced chemiluminescence, stripped and reprobed according to the manufacturer's manual (Amersham, Piscataway, NJ, USA).
Immunohistochemistry for FOXP3
Affinity-purified monoclonal mouse anti-human FOXP3 236A/ E7 was purchased from eBioscience (14-4777, San Diego, CA, USA). Following microwave heat-induced epitope retrieval, sections were incubated for 60 min at room temperature with a 1:50 dilution of FOXP3 and then stained using the DAKO Real EnVision Detection System, Peroxidase/DAB, Rabbit/Mouse (K5007, DakoCytomation, Glostrup, Denmark) by the Techmate 500 Immunostainer. 
Statistical analysis
Statistical analysis was performed using SPSS 13.0 and SAS 9.1 software packages. Statistical significance was attributed to a Pvalue o0.05. Unless indicated otherwise, all continuous data are presented as median (range). As Klemke et al. 10 suggested an inverse correlation between FOXP3 þ Treg and disease stage, our a priori hypothesis was that the presence of FOXP3 is associated with a favourable prognosis and survival. The data obtained from FOXP3 immunostains were compared between the different disease categories, using a linear mixed model (multi-analysis of variance (multi-ANOVA) for repeated measurements, where group is the fixed effect and patient is the random effect. 17 This statistical model also allows for analysis of total variation contributed to by variations between patients in the same group (variance 1) and variations secondary to random effects (variance 2). Survival data were assessed by KaplanMeier method. Patients were considered at risk of death from the day of diagnosis. Patients were censored at the date of the last follow-up. Covariates were initially assessed by log-rank analyses. A Cox proportional hazards model was performed using the number of FOXP3 þ Tregs and morphological group entered as continuous and class variable, respectively. Hazard ratios (HR) are provided with 5-95% confidence intervals (CI). To reach adequate numbers of censoring events, the groups with MF tumour and transformed MF were combined in the Cox regression analysis.
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Results
FOXP3 in cell lines and control tissues
In reactive tonsils and lymph nodes, occasional T lymphocytes in the interfollicular area and in the germinal centres were positive for FOXP3. The staining was always nuclear and very strong in intensity. The specificity of the anti-FOXP3 antibody was demonstrated in western blotting by comparing FOXP3 expression in Jurkat T cells transfected with FOXP3 or a vector control. As shown in Figure 1 (Figure 1 , lower right vs left), indicating that equal amounts of cell lysates had been loaded onto the gel. In addition to wild-type FOXP3, the antibody also recognized a low-molecular splice variant of FOXP3 in CD4 þ T cells with a potent suppressive capacity in vitro 12 (data not shown). To address whether FOXP3 was expressed in cell lines derived from CTCL patients, MF2000 and MF1885 were assayed for FOXP3 expression using western blotting and immunohistochemistry, but none of the cell lines displayed FOXP3 expression (data not shown).
FOXP3 immunostaining in CTCL: labelling of the malignant cells
All CTCL biopsies were suitable for immunohistochemical analyses. Of 86 tumour specimens, only one displayed positive staining for FOXP3 in above 10% of the lymphoma cells. In this case FOXP3 showed nuclear staining in 20% of the neoplastic cells (Figure 2d) . The intensity was moderate and hence weaker than in the tumour-infiltrating Tregs. In the remaining 85 cases, the atypical neoplastic infiltrate was either FOXP3 negative (n ¼ 80) or contained only very occasional weakly positive cells (n ¼ 5).
The FOXP3 þ lymphoma sample originated from a 71-yearold female patient who presented with multiple, centrally ulcerated tumours on the trunk and extremities. Histologically, these lesions showed infiltrates of small-to medium-sized, pleomorphic cells with marked involvement of the epidermis and dense, band-like infiltrates in the upper dermis (Figure 2a) . In the deeper part of the dermis, nodular infiltrates around the vessels were seen. By immunohistology, the lymphoma cells were positive for CD3, CD8, TIA-1 and granzyme B, but not for CD4, CD30 or CD56 (Figure 2a-c) . These features were considered consistent with a diagnosis of an aggressive, epidermiotropic CD8 þ cytotoxic T-cell lymphoma. 18 The clinical behaviour of this case was, as expected for this category of CTCL, aggressive with dissemination to lung and eye at 7 months and death occurring at 9 months after initial presentation.
FOXP3 immunostaining in CTCL: labelling of the tumour-infiltrating Tregs
Results from the staining of Tregs in MF and CTCL unspecified are summarized in Table 1 and Figure 3 . Representative examples are illustrated in Figure 4 . As shown, the tumourinfiltrating Tregs displayed a very strong positivity for FOXP3 and only nuclei were stained. The highest median numbers of FOXP3 þ Tregs was seen in MF with infiltrated plaques (median 68), followed by CTCL unspecified (median 43) and MF with Pair-wise inter-group comparison of the numbers of FOXP3 þ Tregs in different disease categories was performed using a multi-ANOVA approach for repeated measurements. Using MF with infiltrated plaques as reference, statistically significant differences were observed to all CTCL groups. Identical results were found when using either of the other disease categories as reference group (Table 2 ). This shows that the Treg numbers correlate specifically to disease subtype and stage with higher numbers of FOXP3 þ Tregs in early than advanced MF or CTCL unspecified. In addition, a Kruskal-Wallis test was performed and confirmed the statistical significant difference between the groups (P ¼ 0.0001).
All groups displayed a wide range of values for FOXP3 þ Tregs and there was a distinct overlap between the ranges comparing the different groups (Table 1 and Figure 3 ). The total variation was mainly contributed to by variation between the patients in the different groups (variance 1 ¼ 91%), and to a lesser extent due to random effects (variance 2 ¼ 9%).
Cox regression analysis of survival
The survival of all patients with respect to diagnostic group is shown in Figure 5a . A Cox proportional hazards model with morphological type as a class variable demonstrated inferior survival in advanced MF compared to early MF lesions. Furthermore, as anticipated, overall survival for patients with CTCL unspecified was significantly worse than for all MF categories (Figure 5a) .
The relationship between FOXP3 quartiles and survival is shown in Figure 5b . An analysis of the entire MF and CTCL unspecified cohort demonstrated that increasing numbers of FOXP3 þ Tregs were associated with improved survival (P ¼ 0.028; HR ¼ 0.988; CI (0.978, 0.999)).
A final Cox model containing both FOXP3 values and disease type as covariates demonstrated that both numbers of FOXP3 þ Tregs and CTCL disease categories were independent risk factors for death (Table 3 ). This indicates that having high numbers of FOXP3 þ Tregs is associated with improved survival in different CTCL subtypes.
Discussion
Over the past few years the relevance of Tregs in tumour immunosurveillance has attracted considerable attention. Woo et al. 19 were the first to report increased numbers of CD4 þ CD25 þ Tregs in human epithelial tumours. These cells secreted transforming growth factor (TGF)-b, expressed high levels of CTLA-4 and inhibited autologous T-cell proliferation in a dosedependent manner. 20 The impact of Tregs on antitumour immune responses has also been demonstrated in a transgenic murine colon carcinoma model, where Tregs abrogated the CD8 þ T-cell-mediated tumour rejection by specifically suppressing the cytotoxicity of these cells. 21 Furthermore, there is evidence for a significantly enlarged Treg pool in malignant melanoma and carcinomas of the breast, pancreas, lung, ovary and gastrointestinal tract. 6, 20, 22, 23 This increase in Tregs appears to be stage dependent and to correlate inversely with survival rates. [23] [24] [25] In this study of 86 CTCL patients, it is shown that plaque lesions of MF contain increased numbers of tumour-infiltrating FOXP3 þ Tregs compared to more advanced cases with tumours or transformation to large T-cell lymphomas. Importantly, we provide the first evidence that increasing numbers of FOXP3 þ Tregs is associated with improved survival in both MF and CTCL, unspecified. In a smaller study, Klemke et al.
10 also obtained preliminary evidence for stage-related differences in FOXP3 expression in CTCL, but they did not address whether FOXP3 expression was associated with patient survival. However, two reports of follicular lymphoma and Hodgkin's lymphoma have both shown that increasing number of Tregs was a favourable prognostic indicator, 7, 8 similar to the observations in this study, and apparently in contrast to the situation in solid tumours.
How Tregs are recruited to the tumour environment is not clear. Studies in solid tumours have demonstrated that the elevated numbers of Tregs in peripheral blood is related to active proliferation of the Treg pool rather than to redistribution from other lymphoid structures. 26 It has also been shown that epithelial tumour cells and macrophages in the tumour microenvironment attract Tregs by secretion of CCL22, a ligand to CCR4, expressed on tumour-infiltrating Tregs. 25 Taken together, it is possible that both proliferation and migration may contribute to the expansion of Tregs in cancer tissue. Whether similar mechanisms are operative in CTCL is not known. However, it has been shown that a majority of circulating Tregs express skin-homing receptors, including both CLA and CCR4, which can interact with corresponding ligands (CD62E and CCL17) on the dermal microvasculature. 27, 28 Furthermore, in MF CCL17 is unregulated on keratinocytes in lesional skin compared to healthy controls. 29 Thus, it seems that skin can actively recruit memory Tregs from the periphery.
At the cellular level, Tregs suppress the activation and proliferation of CD4 þ and CD8 þ T cells, [30] [31] [32] by inhibition of interleukin (IL)-2 production and induction of cell cycle arrest in these cells, which requires cell-cell contact. 32 In contrast, in vivo studies report that the presence of cytokines, such as IL-10 and TGF-b, might also be necessary for a suppressive milieu. 9, 33 In a recent study Yang et al. 34 demonstrate that intratumoural Tregs inhibit the proliferation and degranulation of CD8 þ T cells in B-cell lymphoma, thereby dampening the antitumour effect of these cells. It is unknown whether a similar mechanism is involved in CTCL. Since malignant T cells and Tregs are derived from the same progenitors it is possible that Tregs might directly suppress the function of malignant T cells. In support of this hypothesis, Tiemessen et al. 11 observed that Tregs from healthy individuals inhibit in vitro proliferation of T cells acquired from CTCL patients.
Regarding FOXP3 labelling of the neoplastic cells, our results indicate that this is seen only very rarely in CTCL. These findings are in keeping with other reports of T-cell malignancies, which have indicated that peripheral T-cell lymphomas, including CTCL, are generally FOXP3 negative with the notable exception of adult T-cell lymphoma/leukaemia. [35] [36] [37] [38] [39] One recent study has indicated that transformation of MF to CD30-positive large T-cell lymphomas is associated with a Treg phenotype. 40 However, the limited number of cases investigated (n ¼ 5) and the lack of controls for the immunolabelling restricts the interpretation of this study.
Adult T-cell lymphoma/leukaemia is recognized as a T-cell lymphoma associated with immunodeficiency and opportunistic infections. 41 This phenomenon has been linked to immune suppression by the neoplastic cells which express FOXP3 in approximately half of the cases. [35] [36] [37] [38] [39] A similar mechanism has been proposed to be operative in CTCL by Berger et al. 9 They found that CD4 þ CTCL cells stimulated with autologous, immature dendritic cells loaded with apoptotic tumour cells could be induced to express CD25, CTLA-4 and FOXP3. In addition, the cells showed upregulation and secretion of both IL-10 and TGF-b, features which are all characteristic of Tregs. Although it cannot be precluded that CTCL cells may be induced to assume Treg characteristics under certain conditions in vitro, the lack of FOXP3 labelling of the neoplastic cells in biopsy samples both in this and previous reports 10, 11, 38 suggests that immune suppression by the neoplastic cells is less likely to be a general phenomenon in CTCL in vivo.
In conclusion, we provide the first evidence that a high frequency of tumour-infiltrating FOXP3 þ Tregs is associated with improved survival rates in MF and CTCL unspecified. Furthermore, our data show increased numbers of FOXP3 þ Tregs in early as opposed to advanced MF. Thus, our data support the notion that Tregs might play a fundamentally different role in lymphoma as compared to solid tumours. 
